Navigation Links
NeoGenomics Awarded $374,000 in R&D Grants from the US Government
Date:11/4/2010

NeoGenomics Awarded $374,000 in R&D Grants from the US Government -- FT. MYERS, Fla., Nov. 4, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Domestic Policy Click to view news release full screen  

NeoGenomics Awarded $374,000 in R&D Grants from the US Government

 

FT. MYERS, Fla., Nov. 4, 2010 /PRNewswire-FirstCall/ --- NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer-focused genetic testing services today reported that it had been awarded two research and development grants totaling $374,479 from the US government under HR: 3590 - Patient Protection and Affordable Care Act (the "Act").

Under the Act, $1 billion was earmarked for qualifying therapeutic discovery projects that show the potential to produce new cost saving therapies, create U.S. jobs, increase the country's competiveness, or significantly advance the goal of curing cancer within the next 30 years.

NeoGenomics submitted two applications under this program for expenses incurred in connection with its new test development activities.  NeoGenomics was awarded $244,479 under the first application, the maximum allowable award per application, and $130,000 under the second application.Doug VanOort, NeoGenomics' Chairman and CEO, said, "We are very pleased to have been awarded these grants.  They are an important recognition of the work we are doing to bring new cancer diagnostic tests to the market.  We expect to receive the funds sometime during the month of November."

About NeoGenomics, Inc.NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.  

For more news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM where you can find a fact sheet on the company, investor presentations, and more.  Interested parties can also access additional investor relations material, including an investment profile and an equity research report, from Hawk Associates at http://www.hawkassociates.com or from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/.

Forward Looking StatementsExcept for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements.  These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.


'/>"/>

SOURCE NeoGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeoGenomics Schedules its Q3 2010 Earnings Release for October 28, 2010
2. NeoGenomics Schedules Its Q4 and Full Year 2009 Earnings Release for February 25, 2010
3. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
4. ECRI Institute Awarded AHRQ Contract to Establish National Healthcare Horizon Scanning System
5. Poniard Pharmaceuticals Awarded $244,479 Grant Under Qualifying Therapeutic Discovery Project Program
6. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
7. Stereotaxis Awarded $1.5 Million in Grants under the Qualifying Therapeutic Discovery Project Program
8. BioSpecifics Technologies Corp. Awarded Two Qualifying Therapeutic Discovery Project Grants
9. Champions Biotechnology Awarded $1.46 million in Grants
10. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
11. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CAMBRIDGE , United Kingdom and  BOSTON ... text analytics provider Linguamatics today announced ... Dow Jones . The agreement allows pharmaceutical companies ... utilizing Linguamatics I2E text mining technology. ... used by 18 of the top 20 global ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm ... its corporate headquarters to a new, more expansive office space in order to ... Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 Silas ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... 28, 2017 , ... AutismOne announced the Board Certified in ... Medicine and available for application on Saturday, May 27, 2017, following Thursday, Friday, ... Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities termed ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With expansion and ... Georgia, in early March. , The seed processing plant opened in Marshallville in 2006, ... 2016. The new office allows opportunity for transition of Patten Seed operations to the ...
Breaking Medicine News(10 mins):